首页>投融资
ACELYRIN
上市
Acelyrin, Inc于2020年7月27日在美国特拉华州注册成立。Acelyrin, Inc是一家处于后期阶段的生物制药公司，专注于识别、收购和加速变革性药物的开发和商业化。自成立以来，公司投入了几乎所有的资源来组织公司、招聘人员、业务规划、获取和开发其候选产品、进行研发、支持其产品开发工作的制造活动、建立和保护其知识产权组合、筹集资金以及为这些活动提供一般和行政支持。
基本信息
-
公司全称ACELYRIN INC
-
类型抗体药物开发商
-
产业领域医药研发/制造
-
公司人数101~500人
-
地址4149 Liberty Canyon Road Agoura Hills California 91301
-
联系电话1-805-7300360
-
邮箱info@acelyrin.com
-
成立时间2020-07-27
投融资
-
2023-05-05上市5.02亿美元未透露
-
2022-09-13C轮3亿美元Westlake Village BioPartnersSamsara BioCapitalMarshall Wace奥博资本Access IndustriesVenBio PartnersCowen Healthcare InvestmentsAyurMaya德诚资本Surveyor CapitalTybourne Capital Management
-
2021-11-16B轮2.5亿美元Samsara BioCapitalMarshall WaceRTW Investments奥博资本VenBio PartnersCowen Healthcare InvestmentsAyurMaya德诚资本Matrix Capital ManagementSurveyor CapitalTybourne Capital Management
-
2020-12-15A轮未透露Westlake Village BioPartners
- 加载更多
相关投融资企业
战略投资
Medic Life Sciences Inc是一家美国的生物技术公司，专注于开发创新的医疗设备和诊断技术。公司致力于改善患者的诊断和治疗体验，通过提供高效、便捷的医疗产品和服务，满足医疗市场的需求。其主要产品线包括医疗影像设备、诊断试剂和生物信息学工具等，通过不断的技术创新和市场拓展，为全球患者带来更好的医疗健康
收并购
Alderley Analytical is an independent Contract Research Organisation (CRO). We offer specialist bioanalytical services to support your drug development programmes, from discovery through to late stage clinical development, focusing on small molecules, large molecules, peptides, biologics and biomarkers.
Our biotech, pharma and CRO clients have discovered that keeping their bioanalysis with one provider means fewer laboratory transfers and no loss of bioanalytical knowledge of the molecule. By simplifying this process, it means less complications helping the rapid development of new drugs.
We take a flexible and responsive approach, using our collective expertise to develop novel bioanalytical methods and deliver your results on-time to the right quality. We also pride ourselves on excellent communication; you’ll find us easy to get hold of and we stay in touch, even if there’s no news to report.
As a GLP and GCP accredited laboratory, we can offer regulatory compliance where needed and are able to validate bioanalytical methods and deliver bioanalytical results to current FDA/EMA guidelines. Get in touch to discuss your bioanalysis requirements today.
Visit our website at www.alderleyanalytical.com for more information.
增发
Theriva Biologics, Inc.成立于1986年，是一家生物技术公司，专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司，开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences，SL进入肿瘤学领域，VCN Biosciences，SL开发了一种新的溶瘤腺病毒平台，设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡，改善共同给药的癌症疗法对肿瘤的获取，并促进患者免疫系统产生强大而持续的抗肿瘤反应。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息